公开(公告)号：US20230089867A1

公开(公告)日：2023-03-23

申请号：US17296895

申请日：2019-11-26

申请人： Novartis AG

发明人： Christopher BECKER ,  Brian Addison DECHRISTOPHER ,  Alec Nathanson FLYER ,  Adam FRIEDMAN ,  Christian GAMPE ,  Andrei Alexandrovich GOLOSOV ,  Philipp GROSCHE ,  Tyler HARRISON ,  Qian LIU ,  Eugene Yuejin LIU, I ,  Justin Yik Ching MAO ,  Lauren Gilchrist MONOVICH ,  Tajesh Jayprakash PATEL ,  Carina Cristina SANCHEZ ,  Liansheng SU ,  Lihua YANG ,  Rui ZHENG

IPC分类号： C07K7/56

摘要： The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein X1, R1, R2, R3, R4, R5, R6, R6′, R7, R7′, R8, R9, R9′, R10, R11, R12, and n are described herein.

公开(公告)号：US20230183286A1

公开(公告)日：2023-06-15

申请号：US17820005

申请日：2022-08-16

申请人： NOVARTIS AG

发明人： David BARNES-SEEMAN ,  Scott Louis COHEN ,  John Louis DIENER ,  Christian GAMPE ,  James ROACHE ,  Amy White ,  Sarah Louise Williams ,  Jun Yuan ,  Frederic Zecri

IPC分类号： C07H21/02 ,  C07F9/6561 ,  C07H19/167 ,  C07H19/207 ,  C07K14/575

CPC分类号： C07H21/02 ,  C07F9/65616 ,  C07H19/167 ,  C07H19/207 ,  C07K14/5759

摘要： The disclosure relates to nucleic acids that contain modifications at the 5′-end, 3′-end or 5′-end and 3′-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.

公开(公告)号：US20180002368A1

公开(公告)日：2018-01-04

申请号：US15536516

申请日：2015-12-16

申请人： NOVARTIS AG

发明人： David BARNES-SEEMAN ,  Scott Louis COHEN ,  John Louis DIENER ,  Christian GAMPE ,  James ROACHE ,  Amy WHITE ,  Sarah WILLIAMS ,  Jun YUAN ,  Frederic ZECRI

IPC分类号： C07H21/02 ,  C07F9/6561 ,  C07H19/207 ,  C07K14/575

摘要： The disclosure relates to nucleic acids that contain modifications at the 5′-end, 3′-end or 5′-end and 3′-ends, and compounds that can be used to make the modified nucleic acids arc disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.